drugset / Trial / NCT05289492
Study of Novel Regimens in Relapsed or Refractory Multiple Myeloma
Phase 1
Terminated
16 enrolled
iTeos Therapeutics
Bristol-Myers Squibb · collabGlaxoSmithKline · collabiTeos Belgium SA · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a multicenter, open-label, phase I/II clinical study, to assess the safety, tolerability, antitumor activity, pharmacokinetics and pharmacodynamics of EOS884448 (also known as EOS-448 or GSK4428859A), alone or in combination with iberdomide with and without dexamethasone in participants with relapsed/refractory multiple myeloma (RRMM).
Timeline
- Start
- 2022-05-01
- Primary completion
- 2023-11-29
- Completion
- 2023-11-29
Outcome
Outcome not reported
Stopped: “Company operational decision. Decision to stop study is not due to safety or efficacy concerns”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Belrestotug | Monoclonal antibody | — | — |
| Subject | Dexamethasone | Small molecule | — | — |
| Subject | Iberdomide | Small molecule | — | — |